# @fixelinstitute on Facebook

- **Type:** Image
- **Original URL:** https://www.facebook.com/1275465578125102/posts/784297720575226
- **Gondola URL:** https://gondola.cc/posts/64720824-fixelinstitute-facebook
- **Thumbnail:** https://img.gondola.cc/tr:w-,h-,fo-auto/postThumbnails/fbd0421d3c.jpg
- **Posted:** 2024-07-03T20:02:12.000+00:00
- **Account Owner:** Grace Huff (@GraceHuff3) — https://gondola.cc/GraceHuff3

## Caption

📝Paper a Day…

New research suggests that sodium-glucose cotransporter 2 (glucose lowering drug) inhibitors may reduce the risk of dementia in individuals with type 2 diabetes. A study from OneFlorida+ Clinical Research Network found that new users of SGLT2 inhibitors had a lower risk of all-cause dementia compared to those using sulfonylureas (another type 2 diabetes med) over a 3.2-year follow-up period. The benefits varied among subgroups, with Hispanic ethnicity and chronic kidney disease playing key roles. This highlights potential personalized approaches to dementia prevention in diabetes management. 🧠💡 #DiabetesResearch #DementiaPrevention #HealthcareInnovation

🔗: https://alzjournals.onlinelibrary.wiley.com/doi/10.1002/alz.14048

## Stats

- **Views:** 0
- **Likes:** 1
- **Shares:** 0
- **Comments:** 0

## Tags

dementiaprevention, healthcareinnovation, diabetesresearch

---
Copyright (c) Gondola